Check 35,000+ stocks against 26 valuation models and 37 quality factors

Encision Inc (ECIA) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Encision Inc $0.02, price $0.01, upside +114.8%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · US · ISIN US29254Q1040

Thin data Sep 27, 2026

Encision Inc

ECIA · US

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value $0.0247 · Strongly undervalued (+114.8%)

!Quality 52/100

!Weak Growth (revenue 5y −3.1 %/yr)

!Loss-making · -6.1% net margin (TTM)

!Low debt · negative free cash flow

!Trails peers (1/9)

!Narrow moat 5/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear $0.0245 to bull $0.0247 Growth analysisrevenue history, year by year Quality 52/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Encision Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range $0.0002 – $1.50 · fair‑value band $0.0245 – $0.0247 · the $0.0115 price screens below the $0.0247 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow Encision in your weekly email

Every Wednesday you see whether Encision is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. It operates through two segments, Product and Service.

Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. It operates through two segments, Product and Service. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. The AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. It also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; AEM EndoShield 2 burn protection systems; AEM 2X enTouch scissors; and electrical engineering activities for external entities. In addition, the company markets AEM monitor product line that is used in conjunction with AEM instruments. It sells its products through a network of direct and independent sales representatives. The company was formerly known as Electroscope Inc and changed its name to Encision Inc. in August 2000. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado.

Stock analysis

Encision Inc (ECIA) currently trades at $0.0115, while our model-based Fair Value estimate is $0.0247, implying the stock looks roughly 53.4% undervalued today.

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.0245 (bear) to $0.0247 (bull), the price of $0.0115 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Encision Inc reported revenue of $6.6M in FY2025 versus $7.5M in FY2021, a compound −3.4%/yr. Reported net income was −$220K in FY2025.

Key figures

Market cap $25.3K · EPS (TTM) $−0.0300 · Net margin −3.4% · Return on equity −21.4% · Return on assets (EBIT) −8.5% · Operating margin −4.2% · Revenue (TTM) $6.3M · Revenue growth (YoY) −2.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).

What moves the price

The share trades about 97% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at 115%, ECIA screens cheaper than that median.

Fair Value models

Bear $0.0245 Fair Value $0.0247 Bull $0.0247

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

NCAV (Graham) $0.0177 $0.0247 $0.0353 54

All 1 models by family

Asset-Based

NCAV (Graham) $0.0177 $0.0247 $0.0353 54

Open the full fair value analysis →

Notify me when ECIA reaches fair value

Put ECIA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 52/100

Of which business quality 50 · Market factors (momentum, volatility) 25

Profitability 40

Margins and returns on capital today

Quality Growth 79

Are margins and returns improving?

Cashflow 7

Earnings quality: real cash, not paper profit

Fin. Strength 42

Balance sheet, leverage, solvency risk

Investment 100

Disciplined investing over empire-building

Low Volatility 32

Calm price path (market factor)

Momentum 35

Price trend over the last 3–12 months (market factor)

52W Momentum 0

Distance to the 52-week high (market factor)

Net Issuance 73

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100

Revenue is shrinking: the last year, the last three and the last five years are all negative.

Revenue growth 1 year

−0.5%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−5.1%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−3.1%

Start year 2020 (pandemic). Over 10 years: −3.8% a year

Revenue growth 28 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+5.7%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−2.0% (2020) → −2.6% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

Watch ECIA, get fair value alerts →

Compare Encision Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 191 stocks

Beats the industry median on 1/8 measures

Overall it trails its industry peers.

Valuation

Quality Score 50 · Below median

Fair Value upside +114.8% · Top 25%

Profitability

Return on assets −5.3% · Bottom 25%

Net margin (TTM) −6.1% · Bottom 25%

Operating margin (TTM) −4.2% · Bottom 25%

Growth and dividend

Revenue growth −2.2% · Bottom 25%

Balance sheet

Debt / equity 0.11× · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

PEG 1.42× · Pricier than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)100 · sector 25

FUTURE (revenue growth)0 · sector 38

PAST (return on equity)0 · sector 27

HEALTH (low debt)95 · sector 96

DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$406.63	$348.72	−14%
EssilorLuxottica Société anonyme EL	€144.60	€159.06	+10%
Becton, Dickinson and Company BDX	$178.07	$104.73	−41%
Medline Inc MDLN	$34.70	$29.06	−16%
Alcon Inc ALC	$63.94	$40.13	−37%
West Pharmaceutical Services, Inc WST	$375.65	$137.81	−63%
Sartorius Stedim Biotech S.A DIM	€208.20	€54.82	−74%
Straumann Holding STMN	CHF 89.80	CHF 45.50	−49%
Sartorius Aktiengesellschaft SRT	€206.50	€42.05	−80%
Solventum Corporation SOLV	$89.50	$134.36	+50%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Encision Inc · Fair Value
$0.0247 +53%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/ECIA" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Encision Inc · Fair Value</span><br><b style="font-size:20px">$0.0247</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+53%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Encision Inc Fair Value". https://www.fairvalue-calculator.com/stock/ECIA

Frequently asked questions

Is Encision Inc (ECIA) overvalued or undervalued?

As of Sep 27, 2026, our model estimates a fair value of $0.0247 versus a price of $0.0115, about +115% upside (undervalued).

What is the fair value of ECIA?

Our model-based fair value for Encision Inc is $0.0247 (as of Sep 27, 2026), built from audited fundamentals. The current price: $0.0115.

What is the quality score of ECIA?

Encision Inc has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Encision Inc (ECIA)?

Our model-based price target is the fair value of $0.0247 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario $0.0245, optimistic scenario $0.0247. It is a calculation from audited fundamentals, not an analyst target.

What is the Encision Inc stock forecast for 2026?

Our models put fair value at $0.0247, about +115% upside versus a price of $0.0115 (undervalued). Cautious scenario $0.0245, optimistic scenario $0.0247. The calculation is refreshed regularly with new filings.

What is the revenue of Encision Inc (ECIA)?

Encision Inc reported trailing-twelve-month revenue of about $6.3M (latest available figure, as of Sep 27, 2026).

What is the intrinsic value of Encision Inc (ECIA)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Encision Inc it is $0.0247 per share (as of Sep 27, 2026), against a price of $0.0115. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).

Is Encision Inc stock overvalued or undervalued in 2026?

As of Sep 27, 2026, ECIA trades below its calculated fair value: price $0.0115, fair value $0.0247, a gap of about +115% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of ECIA?

No. The price is what the market pays today ($0.0115); the fair value is what the company's own numbers justify ($0.0247). For Encision Inc the two are $0.0132 per share apart. That gap is exactly why we show both numbers side by side.

How much is Encision Inc worth?

The market values Encision Inc at about $25.3K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0115; our models calculate a fair value of $0.0247 per share.

What do the bullish and bearish scenarios say about ECIA?

Our models span a range for Encision Inc: cautious scenario $0.0245, base $0.0247, optimistic $0.0247 per share (as of Sep 27, 2026, price $0.0115). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the PEG ratio of ECIA?

The PEG ratio of Encision Inc is 1.42 (P/E divided by earnings growth, as of Sep 27, 2026). That is above 1, so the growth is already paid for in the price.

How solid is the balance sheet of Encision Inc (ECIA)?

Balance-sheet figures for Encision Inc (as of Sep 27, 2026): return on equity −21.4%, debt of 0.11 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.

How far is ECIA from its 52-week high?

Encision Inc trades at $0.0115, about 97% below its 52-week high of $0.3900 and at the low of $0.0115 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0247 is for.

Which stocks are comparable to Encision Inc?

From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Encision Inc stock attractive at the current price?

The data as of Sep 27, 2026: price $0.0115, calculated fair value $0.0247 (+115%), Quality Score 52/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of ECIA calculated?

We run Encision Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0247, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Encision Inc currently trades 53 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Encision Inc (ECIA)?

The closing price on Sep 30, 2026 was $0.0115. Our model-based fair value is $0.0247, about +115% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Encision Inc right now?

The price is below even our cautious bear case ($0.0245). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (52/100) at a price below fair value, the discount is the argument here, not the business quality. The models converge in a tight band ($0.0245 to $0.0247), unusually little disagreement for a valuation.

Key figures of Encision Inc

How large is the market capitalisation of Encision Inc (ECIA)?

The market capitalisation of Encision Inc is $25.3K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What are the earnings per share of Encision Inc (ECIA)?

Earnings per share at Encision Inc are $−0.0300. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Encision Inc (ECIA)?

The net margin of Encision Inc is −3.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Encision Inc (ECIA)?

The return on equity (ROE) of Encision Inc is −21.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Encision Inc (ECIA)?

On an EBIT basis the return on assets of Encision Inc is −8.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Encision Inc (ECIA)?

The operating margin of Encision Inc is −4.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Encision Inc (ECIA)?

Revenue at Encision Inc is growing −2.2% versus a year earlier (3y avg −5.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Encision Inc (ECIA)?

Earnings per share at Encision Inc are growing −70.4% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does Encision Inc (ECIA) generate?

The free cash flow of Encision Inc is −$135K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does Encision Inc (ECIA) carry?

The net debt of Encision Inc is $1.1M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Encision Inc in the live analysis

One click puts Encision Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.